Fosamax Osteonecrosis of the Jaw Attorney: Statute of Limitations in North Carolina

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Assessment

For decades, general health and science information has served as the foundation for public understanding of medical conditions and treatment options. This broad educational context has empowered individuals to make informed decisions about their well-being, from preventive care to managing chronic diseases. Within this framework, discussions of medication safety and potential side effects have always been central, allowing patients and providers to weigh benefits against risks. As the volume of health data has grown, so too has the need for clear, actionable guidance that translates complex scientific findings into practical knowledge. This legacy of accessible health communication now faces a new challenge: addressing the specific concerns that arise when widely prescribed treatments are linked to rare but serious adverse events. The transition from general awareness to focused risk assessment becomes critical when a medication like Fosamax, once a standard intervention for bone health, is associated with osteonecrosis of the jaw. For individuals who have taken this drug, the question shifts from general health maintenance to understanding their personal exposure history and its potential implications. This pivot requires moving beyond broad educational content toward a more targeted inquiry: what legal and medical steps are available for those who may have experienced harm? In North Carolina, this includes examining the statute of limitations for filing claims related to Fosamax and osteonecrosis of the jaw, a process that demands precise knowledge of both medical timelines and legal deadlines.

Understanding Fosamax and Its Link to Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by bone death in the jaw that can occur spontaneously or be triggered by dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ is generally associated with tooth extraction, local infection, and delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In clinical studies, most patients experienced relief of symptoms after stopping the drug, though a subset had recurrence when rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled trials, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The incidence of ONJ is rare, with one study noting it as "rare" compared to atypical femoral fracture, which was "uncommon" (https://pubmed.ncbi.nlm.nih.gov/42046648/). Fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years after three or five years of use (https://pubmed.ncbi.nlm.nih.gov/42046648/).

Legal Considerations for Fosamax-Related ONJ in North Carolina

From a medical perspective, ONJ presents clinically as exposed necrotic bone in the maxillofacial region, often with pain, swelling, or infection. Diagnosis typically involves clinical examination and imaging. The mechanistic pathways linking Fosamax to ONJ are not fully detailed in the provided evidence, but bisphosphonates like Fosamax inhibit osteoclast activity, which can reduce bone turnover and impair healing, particularly in the jaw where dental procedures or infections create a need for bone remodeling. Regarding risk considerations, the adequacy of warnings about Fosamax and ONJ is addressed in the prescribing information. The label explicitly states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, patients and healthcare providers may need to consider whether these warnings were sufficiently communicated, especially given the variable time to onset and the need for dental precautions. For affected patients in North Carolina, attorney-related considerations involve the statute of limitations for filing a lawsuit. The statute of limitations for personal injury claims in North Carolina is generally three years from the date of injury or discovery of the injury. For product liability cases involving Fosamax and ONJ, the timeline between exposure and documented harm is critical. The evidence shows that ONJ can develop from one day to several months after starting the drug, but it may also occur after longer use, as risk increases with duration (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients who developed ONJ after Fosamax use should consult an attorney to determine if their claim falls within the statutory period, considering when the injury was discovered or should have been discovered. In summary, Fosamax is an effective bisphosphonate for osteoporosis, but it carries a rare risk of ONJ, particularly with longer use and in the presence of dental risk factors. The prescribing information includes warnings, but patients should be aware of the need for dental evaluation before and during treatment. For those harmed, legal action in North Carolina must be pursued within the applicable statute of limitations, which depends on the timing of injury discovery.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in North Carolina?

In North Carolina, the statute of limitations for personal injury claims, including product liability cases involving Fosamax and osteonecrosis of the jaw, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. Because ONJ can develop from one day to several months after starting Fosamax, and risk increases with longer use, it is crucial to consult an attorney promptly to determine if your claim falls within this period.

What are the known risk factors for developing ONJ while taking Fosamax?

Known risk factors for osteonecrosis of the jaw include invasive dental procedures (such as tooth extraction, dental implants, or boney surgery), diagnosis of cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures. The risk may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.